Following in the path of M4K Pharma, a new initiative called M4ND Pharma (Medicines for Neurodegeneration) will tackle neurodegenerative diseases such as Parkinson’s disease, thanks to funding from the Krembil Foundation, and will commit to open science practises, open sharing of data, and affordable pricing.
Open Science Drug Discovery Model Expands to Neurodegeneration
Previous
Previous
Study on New Drug Class Targeting ACVR1 Mutation for DIPG
Next
Next